Safety and tolerability of a novel, polyclonal human anti-MERS coronavirus antibody produced from transchromosomic cattle: a phase 1 randomised, double-blind, single-dose-escalation study

BACKGROUND: Middle East respiratory syndrome (MERS) is a severe respiratory illness with an overall mortality of 35%. There is no licensed or proven treatment. Passive immunotherapy approaches are being developed to prevent and treat several human medical conditions where alternative therapeutic opt...

Descripción completa

Detalles Bibliográficos
Autores principales: Beigel, John H, Voell, Jocelyn, Kumar, Parag, Raviprakash, Kanakatte, Wu, Hua, Jiao, Jin-An, Sullivan, Eddie, Luke, Thomas, Davey, Richard T
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5871563/
https://www.ncbi.nlm.nih.gov/pubmed/29329957
http://dx.doi.org/10.1016/S1473-3099(18)30002-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5871563/
https://www.ncbi.nlm.nih.gov/pubmed/29329957
http://dx.doi.org/10.1016/S1473-3099(18)30002-1

Ejemplares similares